MedTrace Logo

Bioequivalence of Bicalutamide New Formulation in Japan

NCT01416870 · Status: TERMINATED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 102

Last updated 2012-01-11

No results posted yet for this study

Summary

The purpose of this study is to investigate the bioequivalence of Bicalutamide new formation with Casodex commercial tablet (80mg) in Japanese healthy male subjects

Conditions

  • Healthy

Interventions

DRUG

ICI176,334-1

Subject will receive single dose of ICI176,334-1

DRUG

Casodex 80 mg tablet

Subject will receive single dose of Casodex 80 mg tablet

Sponsors & Collaborators

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
20 Years
Max Age
45 Years
Sex
MALE
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2010-07-31
Primary Completion
2010-11-30
Completion
2010-11-30

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01416870 on ClinicalTrials.gov